Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: New avenues for cancer chemoprevention and chemotherapy

Current Pharmaceutical Design

Volumn 10, Issue 12, 2004, Pages 1387-1398

  Pellecchia, Maurizio ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Apogossypol; Apoptosis; Bcl 2; Bcl xL; Catechins; Chemoprevention; Combinatin therapy; Gossypol; Polyphenols; Purpurogallin; Theaflavins

Indexed keywords

ANTIOXIDANT; APOGOSSYPOL; BLACK TEA EXTRACT; CATECHIN; CURCUMIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; GOSSYPOL; GOSSYPOL DERIVATIVE; GREEN TEA EXTRACT; ISOFLAVONE; LYCOPENE; NATURAL PRODUCT; PERILLYL ALCOHOL; PHENETHYL ISOTHIOCYANATE; POLYPHENOL; PROTEIN BCL 2; PROTEIN BCL XL; PURPUROGALLIN; RESVERATROL; SULFORAPHANE; THEAFLAVIN; THEAFLAVIN 3,3' DIGALLATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW;

EID: 2342427030     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384880     Document Type: Review

References (61)

1. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-6.
2. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998; 8: 324-30.
3. Fesik SW. Insights into programmed cell death through structural biology. Cell 2000; 103:273-82.
4. Olopade OI, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997; 3: 230-7.
5. Reeve JG, Xiong J, Morgan J, Bleehen NM. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 1996; 73:1193-200.
6. Adams JM and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-26.
7. Wang JL, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-9.
8. Degterev A, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001; 3: 173-82.
9. Tzung SP, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3: 183-91.
10. Enyedy IJ, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44: 4313-24.
11. Kaneko M, et al. Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions. Bioorg Med Chem Lett 2001; 11: 887-90.
12. Chin JW, Schepartz A. Design and Evolution of a Miniature Bcl-2 Binding Protein. Angew Chem Int Ed Engl 2001; 40: 3806-9.
13. L antagonist based on alpha-helix mimicry. J Am Chem Soc 2002; 124: 11838-9.
14. Rutledge SE, Chin JW, Schepartz A. A view to a kill: ligands for Bcl-2 family proteins. Curr Opin Chem Biol 2002; 4: 479-85.
15. Huang Z. The Chemical Biology of Apoptosis: Exploring Protein-Protein Interactions and the Life and Death of Cells with Small Molecules. Chem & Biol 2002; 9: 1059-72.
16. L. J Med Chem 2003; 46: 4259-64.
17. Leone M, et al. Cancer prevention by tea polyphenols is linked to their direct inhibition of anti-apoptotic Bcl-2 family proteins. Cancer Res 2003; 63: 8118-21.
18. L. Chem & Biol 2004; in press.
19. Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 1989; 38: 333-41.
20. Gilbert NE, O'Reilly JE, Chang CJ, Lin YC, Brueggemeier RW. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 1995; 57: 61-7.
21. Wu YW, Chik CL, Knazek RA. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res 1989; 49: 3754-8.
22. Thomas M, von Hagen V, Moustafa Y, Montmasson MP, Monet JD. Effects of gossypol on the cell cycle phases in T-47D human breast cancer cells. Anticancer Res 1991; 11: 1469-75.
23. Wang X. Cytotoxic effect of gossypol in the treatment of metastic adrenal cancer. J Clin Endocrinol Metab 1993; 76: 1019-24.
24. Leblanc ML, Russo J, Kudelka AP, Smith JA. An in Vitro Study of Inhibitory Activity of Gossypol, a Cottonseed Extract, in Human Carcinoma Cell Lines. Pharmacol Res 2002; 46: 551-5.
25. Stein C, Robert AEA, Joseph. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 1992; 30: 480-2.
26. Van Poznak C, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001; 66: 239-48.
27. Wang X, et al. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci 2000; 67: 2663-71.
28. Sattler M, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-6.
29. Zhang M, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003; 66: 93-103
30. Abou-Karam M, Shier WT. Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall. Phytother Res 1999; 13: 337-40.
31. Fung KP, Wu TW, Lui CP. Purpurogallin inhibits DNA synthesis of murine fibrosarcoma L-929 and human U-87 MG glioblastoma cells in vitro. Chemotherapy 1996; 42: 199-205.
32. Jankun J, Selman SH, Swiercz R. Why drinking green tea could prevent cancer. Nature 1997; 387: 561.
33. Yang CS. Inhibition of carcinogenesis by tea. Nature 1997; 389: 134-5.
34. Yang CS, Wang Z-Y. Tea and cancer. J Natl Cancer Inst 1993; 85: 1038-49.
35. Fujiki H, et al. Japanese green tea as a cancer preventive in humans. Nutr Rev 1996; 54: 67-70.
36. Liao S, Umekita U, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995; 96: 239-43.
37. Khafif A, Schantz SP, al-Rawi M, Edelstein D, Sacks PG. Green tea regulates cell cycle progression in oral leukoplakia. Head Neck 1998; 20: 528-45.
38. Liberto M, Cobrinik D. Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Lett 2000; 154: 151-61.
39. Sachinidis A, et al. Green tea compounds inhibit tyrosine phosphorylation of PDGF β-receptor and transformation of A172 human glioblastoma. FEBS 2000; 471: 51-5.
40. Liang YC, Lin-shiau SY, Chen CF, Lin JK. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997; 67: 55-65.
41. Liang YC, et al. Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3′-digallate. Carcinogenesis (Lond) 1999; 20: 733-6.
42. Muto S, et al. Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice. Carcinogenesis (Lond) 1999; 20: 421-4.
43. Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomerase shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 1998; 214: 833-8.
44. Lamy S, Gingras D, Béliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2000; 62: 381-5.
45. Li HC, et al. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 2000; 91: 34-40.
46. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89: 1881-6.
47. Paschka A G, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett 1998; 130: 1-7.
48. Yang GY, Liao J, Kim K, Yurkow EJ, Yang CS. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis (Lond) 1998; 19: 611-6.
49. Islam S, et al. Involvement of caspase-3 in epigallocatechin-3-gallate-mediated apoptosis of human chondrosarcoma cells. Biochem Biophys Res Commun 2000; 270: 793-7.
50. Pan MH, et al. Induction of apoptosis by the Oolong tea polyphenol theasinensin A through cytochrome c release and activation of caspase-9 and caspase-3 in human U937 cells. J Agric Food Chem 2000; 48: 6337-46.
51. Masuda M, Musumi S, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carciroma cell lines. Clin Cancer Res 2001; 7: 4220-9.
52. Bromberg JF, et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
53. Zushi S, et al. Stat3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998; 78: 326-30.
54. Grandis JR, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-32.
55. Lin JK, Lee SF. Inhibition of tumor promotion by blocking the signal transduction. Zool Stud 1995; 34: 67-81.
56. Hsieh YC, Jao HC, Yang RC, Hsu HK, Hsu C. Suppression of protein kinase Calpha triggers apoptosis through down-regulation of Bcl-xL in a rat hepatic epithelial cell line. Shock 2003; 19: 582-7.
57. Yang CS, Maliakal P, Meng X. Inhibition of Carcinogenesis by Tea. Annu Rev Pharmacol Toxicol 2002; 42: 25-54.
58. Hastak K, et al. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003; 22: 4851-4859.
59. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Design 2003; 9(6): 455-66.
60. Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM. et al. Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Curr Pharm Design 2002; 8(22): 1945-58.
61. Harless Smith S and Cancro MP. BLyS: the pivotal determinant of peripheral B cell selection and lifespan. Curr Pharm Design 2003; 9(23): 1833-47.